Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 20 September, 2019

Northern Trust Corp

Form 8.3 - ABBVIE INC

RNS Number : 1625N
Northern Trust Corporation
20 September 2019
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

 Northern Trust Corporation

Company dealt in

 AbbVie Inc

Class of relevant security to which the dealings being disclosed relate (Note 2)

 Common Stock USD 0.01

Date of dealing

 19th  September  2019

 

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 21,182,418   1.43%

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 21,182,418   1.43%

 

             

 

* Note: The difference in holdings from yesterday and today not explained by transactions, can be explained by stock transfers of 364 securities into the accounts and 957 securities out of the relevant accounts.

 

 

 

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

             

 

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit ($)

BUY

160

71.67

BUY

37

71.67

SELL

31

71.67

BUY

6

71.67

BUY

18

71.67

BUY

175

71.7543

SELL

17

71.81

BUY

11102

71.4071

BUY

23

71.67

BUY

144

71.67

BUY

144

71.67

BUY

90

71.81

SELL

134

71.88

BUY

561

71.694

SELL

334

71.75

SELL

333

71.75

SELL

333

71.75

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

 

 

 

 

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

 

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any

 relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            NO

 

Date of disclosure

 20th  September 2019

Contact name

 Luke Piscina

Telephone number

 0207 982 3697

If a connected EFM, name of offeree/offeror with which connected

 

 

If a connected EFM, state nature of connection (Note 10)

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEURAORKBAKUAR

a d v e r t i s e m e n t